Get In Touch

Kingsdale has protected and secured shareholder votes for more Canadian boards than any other firm. If you are a North American issuer, the time to engage us is before the situation demands it.

By providing your data, you agree to our Privacy Policy

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Subscribe to Our Newsletter

Article hero background
Insights
·
News

Wes Hall on What Boards Must Do Before the CUSMA Review

Kingsdale Advisors Founder and CEO Wes Hall is featured in the March/April 2026 edition of ICD's Director Journal, weighing in on one of the most consequential questions facing Canadian business leaders right now: what should boards be doing before the CUSMA review?

Wes, who sits on the Prime Minister's Council on Canada-U.S. Relations, is direct about where things stand. Free trade with the United States, as we have known it, is likely over. What comes next will be a trade agreement, but not a free one. For boards that have been operating on the assumption that North American trade will eventually return to normal, that distinction should be a wake-up call.

The article lays out a clear-eyed framework for directors navigating this shift. That means modelling downside scenarios beyond CUSMA, rethinking supply chains, and preparing for permanently higher tariffs not as a temporary disruption, but as the new baseline. The boards stress-testing these scenarios today will be far better positioned than those waiting to see how negotiations unfold.

As Wes puts it, “It has to be baked in now. We can't just hope and pray.”

The piece also addresses the broader structural challenge facing Canadian companies, including the urgent need to diversify trade relationships, reduce dependence on the U.S. market and build the kind of world-class businesses capable of competing globally. The message throughout is consistent: complacency is no longer an option.

Read the full article, “A Playbook for Tariffs and Uncertainty: What Directors Should Do Before the CUSMA Review,” in ICD’s Director Journal.

Directors looking for strategic advice to get ahead of what could be a very different trade landscape by year's end, please email strategy@kingsdaleadvisors.com.

Article side image

Latest Insights

News
8.1.2025

2025 Proxy Season: Kingsdale Delivers 100% Win Rate

Kingsdale achieved a perfect track record for clients navigating shareholder activism and other special situations. The firm also advised on more than C$22 billion in shareholder approved or completed M&A transactions year-to-date.

2025
Read more
Case Study

M&A Case Study: How One Dissenting Shareholder Nearly Derailed a $201M Acquisition

What started as a straightforward acquisition of Payfare by Fiserv quickly turned complicated when a major shareholder decided to block the deal. With the transaction hanging in the balance, here's what it took to get 80% approval.

2025
Read more
Publication

ISS 2026 Benchmark Policy Updates: What You Need to Know

ISS has announced updates to its 2026 Benchmark Policies, spotlighting long-term pay-for-performance alignment, enhanced scrutiny on director compensation, and a global push toward harmonization. These changes signal a clear trend: investors expect durability, transparency, and strategic disclosure.

2025
Read more
Business district aerial

When The Stakes Are Highest, Business Leaders Choose Kingsdale

Business district aerial

When The Stakes Are Highest, Business Leaders Choose Kingsdale